What percentage of Breast Imaging-Reporting and Data System (BI-RADS) 4 lesions are malignant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: March 22, 2025 • View editorial policy

From the Guidelines

Approximately 20-30% of BI-RADS 4 breast lesions are malignant. The BI-RADS (Breast Imaging Reporting and Data System) category 4 indicates a suspicious abnormality that requires biopsy for definitive diagnosis. This category is further subdivided into 4A (low suspicion, 2-10% risk of malignancy), 4B (moderate suspicion, 10-50% risk of malignancy), and 4C (high suspicion, 50-95% risk of malignancy) 1. The wide range in malignancy rates reflects this subcategorization, with the overall average falling around 20-30%.

Key Points to Consider

  • The BI-RADS category 4 lesions have an intermediate probability of cancer, ranging from 3% to 94% 2
  • Tissue diagnosis using core needle biopsy or needle localization excisional biopsy with specimen radiograph is necessary for BI-RADS categories 4 and 5 lesions 1
  • When a patient receives a BI-RADS 4 classification, a tissue biopsy is recommended regardless of which subcategory they fall into, as imaging alone cannot definitively determine whether the lesion is benign or malignant
  • The biopsy results will guide further management decisions, which may include additional imaging, surgical excision, or cancer treatment if malignancy is confirmed ### Management Recommendations
  • For BI-RADS category 4 lesions, tissue diagnosis is necessary to determine the presence of malignancy
  • Core needle biopsy is the preferred method for tissue diagnosis
  • Concordance between the pathology report and the imaging finding must be obtained when a needle biopsy is performed 1

From the Research

BI-RADS 4 Lesions Malignancy Percentage

  • The percentage of Breast Imaging-Reporting and Data System (BI-RADS) 4 lesions that are malignant varies across different studies, with reported rates including: + 38.7% malignant and 61.2% benign in a study of 186 BI-RADS 4 nonpalpable breast lesions 3 + 17.8% of BI-RADS 4 lesions were malignant in a study of 429 lesions other than primary cancer initially assessed at preoperative MRI 4
  • Subcategories of BI-RADS 4 lesions also have different malignancy rates, including: + 19.5% for subcategory 4A, 41.5% for subcategory 4B, and 74.3% for subcategory 4C in a study of 186 BI-RADS 4 nonpalpable breast lesions 3 + 1.8% for subcategory 4A, 11.8% for subcategory 4B, and 67.5% for subcategory 4C in a study of 434 category 2-5 lesions on MRI 5

Factors Influencing Malignancy Rates

  • The likelihood of malignancy in BI-RADS 4 lesions can be influenced by various factors, including: + Lesion characteristics, such as shape, margin, and echo pattern 3 + The presence of other lesions, such as category 5 or 6 lesions 5 + The use of structured integration of BI-RADS criteria, such as the Kaiser Score (KS) 6

Clinical Implications

  • The management of BI-RADS 4 lesions depends on various factors, including the likelihood of malignancy and the presence of other lesions 4
  • Annual follow-up may be adequate for preoperative MRI-detected BI-RADS 3 lesions and BI-RADS 4 lesions followed up after benign-concordant biopsy 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.